This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

ICAD Reports Third Quarter Financial Results

Stocks in this article: ICAD

iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of cancer, today reported financial results for the three and nine months ended September 30, 2011.

Ken Ferry, President and CEO of iCAD, commented, “Our third quarter results feature strong revenue growth in both our cancer detection and brachytherapy businesses, with each area posting double-digit revenue gains sequentially and over the same period last year.

“Our brachytherapy business continues to gain momentum driven by the growing interest in breast intraoperative radiation therapy (“IORT”). We recently participated in the annual meeting of the American Society for Therapeutic Radiology and Oncology, where we were extremely encouraged by the high level of interest in the Axxent® eBx™ platform by the clinical community. Adding to this momentum, new reimbursement codes for IORT were assigned by the American Medical Association and reimbursement payment rates from the Centers for Medicare and Medicaid are currently anticipated by November 1 st. We believe compelling clinical data supporting the use of IORT in breast cancer treatment combined with appropriate coding and reimbursement will be strong catalysts for enhancing the adoption of IORT and driving revenue growth for our brachytherapy platform.

“Our cancer detection business also performed well in the quarter, with much stronger demand in the U.S. for our Digital Mammography and MRI products. Our mammography business has received a positive response to a new CAD solution that connects to multiple brands of digital mammography equipment simultaneously within a department. In addition, our new product platform for use with breast and prostate MRI continued to achieve strong comparative growth on a quarter and year-to-date basis.

“Overall, we were quite pleased with the progress that was achieved in the quarter. It is gratifying to see results of our strategy to provide a broader offering of solutions to the oncology market, and the traction gained by each of our businesses," concluded Mr. Ferry.

1 of 7

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,387.21 -291.49 -1.65%
S&P 500 2,029.55 -27.54 -1.34%
NASDAQ 4,681.4970 -90.2660 -1.89%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs